A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis
Public ClinicalTrials.gov record NCT00533091. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1B, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Safety of Multiple-Dose, Intravenously Administered MEDI-545, A Fully Human Anti Interferon-Alpha Monoclonal Antibody, In Adult Patients With Dermatomyositis or Polymyositis
Study identification
- NCT ID
- NCT00533091
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- MedImmune LLC
- Industry
- Enrollment
- 51 participants
Conditions and interventions
Conditions
Interventions
- MEDI-545 Biological
- Placebo Other
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2008
- Primary completion
- Jul 31, 2010
- Completion
- Sep 30, 2010
- Last update posted
- May 27, 2012
2008 – 2010
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Scottsdale | Arizona | 85258 | — |
| Research Site | Stanford | California | 94305 | — |
| Research Site | Whittier | California | 90606 | — |
| Research Site | Fort Lauderdale | Florida | 33334 | — |
| Research Site | Miami | Florida | 33136 | — |
| Research Site | Evansville | Indiana | 47714 | — |
| Research Site | Kansas City | Kansas | 66160 | — |
| Research Site | Baltimore | Maryland | 21224 | — |
| Research Site | Cumberland | Maryland | 21502 | — |
| Research Site | Boston | Massachusetts | 02115 | — |
| Research Site | Lebanon | New Hampshire | 03756 | — |
| Research Site | Lake Success | New York | 11042 | — |
| Research Site | Portland | Oregon | 97239 | — |
| Research Site | Duncansville | Pennsylvania | 16635 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00533091, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 27, 2012 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00533091 live on ClinicalTrials.gov.